Table 10 CSF findings during acute attacks (first LP/event) and during remission (last LP/event)

Pleocytosis

Samples

45/81 (55.6%)

3/11 (27.3%)

p = n.s.

WCC

Cells/μl

13 (0–256;81)

4 (0–35;11)

p < 0.04

WCC > 100/μl

Samples

10/81 (12.3%)

0/11 (0%)

p = n.s.

OCB

Samples

9/79 (11.4%)

0/8 (0%)

p = n.s.

QIgG > Q_lim(IgG)

Samples

12/62 (19.4%)

0/7 (0%)

p = n.s.

QIgG

Ratio

2.35 (0.83–8.16; 61)

1.63 (1.32–1.74; 6)

p < 0.03

IgG–IF > 10%

Samples

5/60 (8.3%)

0/6 (0%)

p = n.s.

QIgM > Q_lim(IgM)

Samples

15/51 (29.4%)

0/6 (0%)

p = n.s.

QIgM

Ratio

0.43 (0–7.33; 50)

0.23 (0.13–0.46; 5)

p = n.s.

QIgA > Q_lim(IgA)

Samples

15/52 (28.8%)

1/5 (20%)

p = n.s.

QIgA

Ratio

1.42 (0–16.06; 51)

0.83 (0.64–1.6; 5)

p = n.s.

QAlb > Q_lim(Alb)

Samples

31/64 (48.4%)

0/6 (0%)

p < 0.04

QAlb

Ratio

4.52 (1.79–11.73; 63)

3.29 (2.63–3.66; 6)

p = n.s.

CSF TP elevated

Samples

18/77 (23.4%)

1/9 (11.1%)

p = n.s.

CSF TP concentrations

mg/dl

31 (13.4–97.2; 77)

22.1 (10–56.6; 9)

p = n.s.

CSF TP > 100 mg/dl

Samples

0/79 (0%)

0/9 (0%)

p = n.s.

CSF l-lactate elevated

Samples

19/59 (32.2%)

2/6 (33.3%)

p = n.s.

CSF l-lactate concentrations

mg/dl

1.6 (0.9–2.83; 57)

1.7 (1–2.11; 6)

p = n.s.

CSF l-lactate > 3 mmol/l

Samples

0/59 (0%)

0/6 (0%)

p = n.s.

Time since attack onset

Days

2 (0–40; 84)

48 (48–3595; 11)